Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round
Focusing on small molecule drug discovery and development for cancer and autoimmune diseases BOSTON, Nov. 24, 2021 /PRNewswire/ -- Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing. This financing round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred...
Source: asiaone.com